- ISIN
- US7469641051
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 28, 2018
Highlights
- Market Cap
- $178.17M
- Enterprise Value
- $144.65M
- EPS (TTM)
- $3.20
- PE Ratio
- 3.95
- Total Revenue (TTM)
- $53.74M
- Gross Profit (TTM)
- $53.56M
- EBITDA (TTM)
- $21.97M
- Year Range
- $1.35 - $14.85
- Target Price
- $13.00
- ROA (TTM)
- 64.16%
- ROE (TTM)
- 88.21%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
QTTB Performance Chart
Q32 Bio Inc (QTTB) is up 280.7% since the beginning of the year. At $13 per share, QTTB is trading 14.9% below its 52-week high of $15. Investors who bought $1,000 worth of QTTB shares 5 years ago would now be looking at an investment worth $98.
Loading charts...
Returns By Period
Q32 Bio Inc (QTTB) has returned 280.72% so far this year and 656.89% over the past 12 months.
Q32 Bio Inc
- 1D
- -0.47%
- 1M
- 100.63%
- YTD
- 280.72%
- 6M
- 327.03%
- 1Y
- 656.89%
- 3Y*
- -12.27%
- 5Y*
- -37.17%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.50%
- 1M
- 0.31%
- YTD
- 8.56%
- 6M
- 8.85%
- 1Y
- 24.33%
- 3Y*
- 19.37%
- 5Y*
- 11.84%
- 10Y*
- 13.61%
QTTB Monthly Returns History
Based on dividend-adjusted daily data since Mar 28, 2018, QTTB's average daily return is +0.05%, while the average monthly return is +0.71%. At this rate, an investment would double in approximately 8.2 years.
Historically, 46% of months were positive and 54% were negative. The best month was Jul 2024 with a return of +112.1%, while the worst month was Dec 2024 at -87.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, QTTB closed higher 47% of trading days. The best single day was Jul 10, 2025 with a return of +119.9%, while the worst single day was Dec 11, 2024 at -75.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.87% | 17.53% | 40.79% | -12.77% | 97.32% | 14.39% | 280.72% | ||||||
| 2025 | -11.92% | -25.08% | -27.31% | -3.03% | 8.12% | -13.87% | 48.99% | -22.97% | 15.79% | 41.92% | -22.06% | 51.60% | -3.49% |
| 2024 | 10.20% | 37.31% | 2.90% | 60.80% | -6.93% | -29.61% | 112.14% | 14.18% | 2.62% | 5.85% | -43.02% | -87.22% | -68.57% |
| 2023 | 24.60% | -3.18% | -32.24% | -7.77% | 2.81% | -9.39% | 57.06% | -13.67% | -2.50% | -11.11% | -48.94% | 14.50% | -51.75% |
| 2022 | 2.20% | -6.18% | -12.89% | -45.39% | -11.45% | 34.01% | 9.14% | 8.84% | -31.20% | -7.45% | 3.36% | -18.18% | -65.38% |
| 2021 | 7.62% | -11.60% | -12.38% | -28.06% | -1.92% | 9.49% | -12.52% | 13.05% | 9.46% | -27.19% | -11.87% | -27.92% | -67.76% |
Benchmark Metrics
Q32 Bio Inc has an annualized alpha of -4.23%, beta of 1.11, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since March 28, 2018.
- This stock participated in 153.82% of S&P 500 Index downside but only -23.27% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -4.23%
- Beta
- 1.11
- R²
- 0.04
- Upside Capture
- -23.27%
- Downside Capture
- 153.82%
Return for Risk
Risk / Return Rank
QTTB ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Q32 Bio Inc (QTTB) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| QTTB | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.47 | ||
| Sortino ratioReturn per unit of downside risk | +2.13 | ||
| Omega ratioGain probability vs. loss probability | 1.57 | 1.34 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 12.70 | 2.53 | +10.17 |
| Martin ratioReturn relative to average drawdown | 23.97 | 11.37 | +12.60 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Q32 Bio Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Q32 Bio Inc was 99.75%, occurring on Jul 7, 2025. The portfolio has not yet recovered.
The current Q32 Bio Inc drawdown is 97.69%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -99.75%Jul 2025 | 6y 3mo | — | 7y 2moApr 2019 - now |
2018 bear market2018 | -32.43%Aug 2018 | 4mo 15d | 3mo 25d | 8mo 10dMar 2018 - Dec 2018 |
Rate-hike selloffLate 2018 | -25.93%Dec 2018 | 10d | 2mo 6d | 2mo 16dDec 2018 - Feb 2019 |
2019 correction2019 | -12.88%Mar 2019 | 22d | 14d | 1mo 6dFeb 2019 - Apr 2019 |
Drawdown Indicators
| QTTB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.75% | -56.78% | -42.97% |
Max Drawdown (1Y)Largest decline over 1 year | -51.14% | -9.10% | -42.04% |
Max Drawdown (3Y)Largest decline over 3 years | -97.31% | -18.90% | -78.41% |
Max Drawdown (5Y)Largest decline over 5 years | -99.13% | -25.43% | -73.70% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -97.69% | -2.34% | -95.35% |
Average DrawdownAverage peak-to-trough decline | -72.93% | -10.72% | -62.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.07% | 2.02% | +25.05% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Q32 Bio Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Q32 Bio Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for QTTB, comparing it with other companies in the Biotechnology industry. Currently, QTTB has a P/E ratio of 4.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for QTTB relative to other companies in the Biotechnology industry. Currently, QTTB has a P/S ratio of 3.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for QTTB in comparison with other companies in the Biotechnology industry. Currently, QTTB has a P/B value of 3.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with QTTB
Add Q32 Bio Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with QTTB